
Samsung Biologics Launches CHF 1.46 Billion Tender Offer for PolyPeptide
Samsung Biologics has published its formal offer prospectus to acquire PolyPeptide, deepening its push into peptide manufacturing as CDMOs race to expand capacity for GLP-1 and other peptide-based drugs.



























































